Kornimate/medical-research-clean huggingface dataset:
independent housing and support for people with severe mental illness

Conditions: Severe Mental Disorder

Summary: background: adequate and stable housing conditions are fundamental for the psychiatric rehabilitation of individuals with severe mental illness (smi). a common approach in psychiatric rehabilitation relies on a continuum of residential services that aims at enabling the person with smi to live eventually independently. current state of research, however, shows clearly that most persons in question remain in residential care settings or other treatment as usual conditions (rcs/tau). the independent housing and support (ihs) scheme is a new model that aims at direct placement in an independent accommodation in the community. support is provided according to individual needs in a permanent housing situation without time limit. up to now, randomized controlled trials (rcts) to evaluate the effectiveness of ihs have only been conducted with homeless populations in north america. the purpose of the present study is to evaluate ihs compared to traditional rcs/tau for non-homeless persons with severe mental illness. with this study, the investigators aim at demonstrating that ihs is not inferior to rcs/tau. the rationale for utilizing a non-inferiority approach is based on the current state of research and on research that has shown strong preferences for ihs against rcs/tau by people with smi. methods: as the preference issue makes rcts in housing research difficult the investigators will use a specific time window in zurich that allows conducting a rct due to a scarcity of ihs settings and will combine the rct with a comparative observational study in berne where ihs is already well-established. at the zurich site, a rct compares the effects of living with ihs against living in residential care. at the berne site, an observational study design (osd) will be applied in connection with the same types of housing as in zurich. propensity scoring will be utilized to minimize the risk of bias in the osd. a number of n=56 eligible subjects in zurich and n=112 subjects (due to specific requirements for propensity scoring) in berne complying with the inclusion criteria will be recruited and allocated to intervention and control groups according to the site-specific study designs. recruitment period will last 21 months.


Eligibility criteria:
inclusion criteria: * primary mental disorder according to icd-10-categories * age 18 to 65 years * ability to communicate in german language * ability to give informed consent * written informed consent as documented by signature * ability to take medication if indicated * willingness to handle out of pocket expenses or established assistance by custodian/guardian exclusion criteria: * severe learning disability, intoxication, delirium, dementia * participants lacking capacity * indication for hospital treatment due to acute symptomatology at admission * acute endangerment of self or others

Keywords: psychiatric rehabilitation supported housing residential care
community-acquired pneumonia - study on the initial treatment with antibiotics of lower respiratory tract infections

Conditions: Community-acquired Pneumonia

Summary: the purpose of this study is to compare the cost(effectiveness) of three existing antibiotic strategies for patients with community-acquired pneumonia admitted to the hospital, but not the icu.


Eligibility criteria:
inclusion criteria: * all patients admitted to one of the participating hospitals needing treatment for cap, not being admitted to the icu are eligible for study inclusion. * admission is defined as hospital stay for more than 24 hours. exclusion criteria: * patients who are readmitted with cap within 2 weeks after a previous episode are not eligible. * patients with cystic fibrosis are not eligible.

Keywords: pneumonia, anti-bacterial agents, (cost)efficacy
pharmacogenetics sampling of the cc-90007-cp-003 study cohort

Conditions: Hepatic Insufficiency

Summary: this is a multi-center observational follow-up study to collect saliva samples that allow pharmacogenetic analysis of the subjects that participated in the cc-90007-cp-003 study. approximately 28 subjects with moderate and severe hepatic impairment and healthy control subjects with normal hepatic function will be enrolled.


Eligibility criteria:
inclusion criteria: each subject must satisfy all of the following criteria to be enrolled in this study: 1. subject must understand and voluntarily sign an icf prior to any study-related assessments/procedures being conducted. 2. subject is able to communicate with the investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules and other protocol requirements. 3. subject is willing and able to adhere to the study visit schedule and other protocol requirements. 4. subject participated in the cc-90007-cp-003 study. exclusion criteria: the presence of any of the following will exclude a subject from enrollment: 1. subject has any condition which places the subject at unacceptable risk if he/she were to participate in the study. 2. subject has any condition that confounds the ability to interpret data from the study. sponsor's medical monitor should be consulted on suspected conditions under this exclusion criterion, prior to exclusion.

Keywords: hepatic impairment cc-90007-cp-003 healthy subject
the use of cranberries in women with preterm premature rupture of membranes

Conditions: Fetal Membranes, Premature Rupture; Premature Birth

Summary: cranberries have been proved to reduce the rate of urinary tract infections in a population of women with recurrent urinary tract infections in previous studies. the purpose of the study is to examine the efficacy of cranberries in pregnant women with preterm premature rupture of membranes in a)prolonging the latent period (=the time period between the time the water broke and delivery of the fetus) and b)reduction of infectious morbidity of both the mother and infant.

preterm premature rupture of membranes (pprom) complicates 2-3.5% of pregnancies and precipitates labor in 30-40% of preterm deliveries. the common practice in early pprom with no evidence of chorioamnionitis is admission for close surveillance, antibiotic treatment and steroids for fetal lung maturation (until 32 weeks gestation. intraamniotic infection is evident in up to 75% of women who develop labor during admission. the infection is for the most an ascending infection. cranberries have been recognized by the american indians as a natural means for preventing urinary tract infection. the mechanism of action includes acidification of urine and inhibition of adhesion of pili-harboring bacteria to the transitional epithelium of the urinary tract. we assume that cranberries will lower the rate of maternal urinary tract infection. moreover, the active ingredients will pass transplacentally to the fetus, will be secreted in its urine hence, in the amniotic fluid. the active substances would coat the vagina and bring about their effect also in that environment. having in mind that most if not all chorioamnionitis infections are caused by ascending infection, the cranberries might lengthen the latent period and reduce infectious maternal and neonatal morbidity.

Eligibility criteria:
inclusion criteria: * proven premature rupture of membranes * less than 35 weeks of gestation with good obstetrical dating * no suspicion of amnionitis * signed informed consent exclusion criteria: * known sensitivity / allergy to cranberries * women treated with warfarin * drug intolerance

Keywords: urinary tract infection endometritis respiratory distress syndrome necrotizing enterocolitis intraventricular hemorrhage latent period neonatal infection
long-term recovery: longitudinal study of neuro-behavioral markers of recovery and precipitants of relapse

Conditions: Alcohol Use Disorder

Summary: the goals of this study are to provide a scientific understanding of recovery and relapse, as well as to identify novel targets for future relapse prevention interventions.

the study will characterize long-term trajectories of recovery from alcohol use including the associated changes in psychosocial functioning and relapse status. by using an accelerated longitudinal design, competing neurobehavioral decision systems (cnds) functioning (measured using delay discounting), psychosocial functioning, and relapse will be characterized over a 12-year period for individuals in alcohol use disorder (aud) recovery.

Eligibility criteria:
inclusion criteria: 1. be ≥18 yrs old 2. meet lifetime dsm-5 aud criteria 3. have a recovery initiation date less than 10 years prior to the time of enrollment 4. be able to read independently 5. be free of legal problems that could limit participation 6. reside in the u.s. 7. anticipate continued internet access (to ensure ongoing contact and data collection) 8. be a registrant of the international quit and recovery registry (iqrr) exclusion criteria: * minors will not be included * prisoners will not be included. if participants become incarcerated during this study, they will not be contacted to complete assessments during their incarceration. if the incarcerations ends during the study, they may be contacted to participate in assessments. * adults who are not capable of consenting on their own behalf
outcome of neo-adjuvant chemotherapy followed by breast conservative surgery in breast cancer in upper egypt

Conditions: Breast Cancer

Summary: systemic chemotherapy along with radiotherapy has been successfully used to post-operatively manage patients following tumour resection in breast cancer. this was further supported with clinical trials conducted in the 1970s and 1980s which shows significant improvement in progression-free of tumours and overall survival rates in patients who undergo chemotherapy for operable breast cancer.(1)-(2) neoadjuvant chemotherapy on the other hand, involves the administration of the chemotherapeutic agents some weeks before appropriate breast surgery. this induces reduction in the tumour size and allows for breast conservative surgery instead of mastectomy in some cases. techniques for tumour localization in neoadjuvant chemotherapy using metallic markers allowing lower excision of breast tissue without compromising margins and breast conservation being feasible in many patients have evolved over time.(3)-(7)-(9) however, there are recent concerns questioning the increase use of neoadjuvant chemotherapy in breast cancer it as it may not be beneficial to patients in the long run.(10)

this will consist of six cycles of fec-100 regimen followed by surgery. the decision on the type of surgery (breast conservative surgery or mastectomy) will be taken on the final assessment of the disease after the six cycle. neoadjuvant chemotherapy regimen will consist of six cycles of fluorouracil 500mg/m2 , epirubicin 75mg/m2 and cyclophosphamide 500mg/m2 administered intravenously at three week interval. surgery was planned to be performed within 4-6 weeks after the six course of chemotherapy.

Eligibility criteria:
inclusion criteria:1- female patients diagnosed with breast cancer and are attending oncology or surgical unit of assiut university hospital . 2- breast cancer will be diagnosed by core-needle biopsy. 3- all patients must have complete history and physical examination (including careful assessment of breast and axillary lymph nodes). 4- all patients must have routine laboratory tests (cbc, liver and renal function tests, and alkaline phosphatase) and radiological tests (chest x-ray, pelvic-abdominal ultrasound, bilateral mammography with confirmatory ultrasound and complete echocardiography to assess the cardiac function). 5- written consent from patients. - exclusion criteria: * 1- elderly patients more than 70years old. 2- previous treatment for breast cancer. 3- presence of co-existing malignancies. 4- pregnancy or lactation at time of diagnosis. 5- severe renal, hepatic or haematological abnormalities. 6- bilateral breast cancer. 7- advanced breast cancer
lipid efficacy/tolerability study (0524a-020)

Conditions: Primary Hypercholesterolaemia; Mixed Hyperlipidaemia

Summary: a 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of mk0524a on lipids and tolerability. there will be 9 scheduled clinic visits, and 3 treatment groups. a patient can be randomly assigned to 1 of the 3 treatment groups.


Eligibility criteria:
inclusion criteria: * patients 18 to 85 years of age with primary hypercholesterolemia or mixed hyperlipidemia with ldl-c below 100 mg/dl for high risk patients (patients with coronary artery disease (chd). * have medical conditions considered to be chd equivalent). * ldl-c below 130 mg/dl for patients with multiple risk factors. * ldl-c between 130 and 190 mg/dl for patients with low risk and triglycerides \</= to 350 mg/dl. exclusion criteria: * a condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study, patients \< 20% compliance, patients with chronic medical conditions, patients with unstable doses of medications. * pregnant or lactating women, or women intending to become pregnant are excluded. * patient with diabetes mellitus that is poorly controlled, newly diagnosed, has recently experienced repeated hypoglycemia or unstable glycemic control, or is taking new or recently adjusted antidiabetic pharmacotherapy (with the exception of +/- 10 units of insulin). * patients with the following conditions: chronic heart failure, uncontrolled/unstable cardiac arrhythmias, unstable hypertension, active or chronic hepatobiliary or hepatic disease, hiv positive, gout (within 1 year).
assessment of the effectiveness of a program of preparation to pregnancy and delivery

Conditions: Lumbago; Anxiety

Summary: introduction: randomized studies on programs implemented during pre-natal care that offer information and physical activities preparing pregnant women for delivery are scarce in the scientific literature. objective: to evaluate the effectively of the program for preparation of pregnant women for delivery on the prevention of physical and psychological difficulties and problems during pregnancy and delivery in nulliparous women participating in the program. subjects and methods: a randomized clinical single blind trial will be conducted with 192 pregnant nulliparous women allocated to participate or not of the program activities. the women allocated to the study group will participate of physical and educational activities at each pre-natal consultation and will receive orientation on the exercises they will perform at their home. participants of the non-interventional group will follow the habitual routine care at the service. participants will be selected among nulliparous low risk pregnant women aged between 16 and 40 years old after the 20th week of gestation. data analysis: will be performing by intention to treat. for the continues variables the t-student or wilcoxon test will be performing; for the categorical variables the tests x² or fisher, and the risk estimate will be estimated using a relative risk with 95% ci. anova will be use for measures between the groups and along time, and correlation tests for anxiety and physical activity with gestational and perinatal variables.

participants, 192 nulliparous women that receive pre-natal care, allocated according to randomization into two groups: group one in which the women who participate in a program with physical and educational activities and the non-interventional group that will not receive the intervention and will follow a regular pre-natal care at routine of the service. the designation of participants will be performed, after informed consent will be sign, by opening sequentially envelopes previously sealed and numbered that will contain the information, previously generated by a computer system.

Eligibility criteria:
inclusion criteria: 1. pregnant women aged between 16 and 40 years old 2. gestational age \>20 weeks 3. nulliparous women 4. single fetus 5. performing pre-natal care. exclusion criteria: 1. pathological heart condition 2. diabetes 3. hypertension 4. asthma bronchial 5. hiv+ 6. gestational hypertension 7. gestational diabetes 8. pre-eclampsia 9. persistent bleeding 10. premature labor 11. cervical incompetence 12. acute infection with fever 13. restriction in fetal growth 14. indication of elective caesarian-section 15. in psychotherapy 16. performing other physical activity more than once a week.

Keywords: preparation of the delivery lumbago anxiety urinary incontinence
a study on how cagrisema affects levels of atorvastatin and warfarin in the blood of participants with excess body weight

Conditions: Obesity

Summary: this study will look at how cagrisema affects the blood levels of atorvastatin and warfarin. the study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking cagrisema and if this changes after the participant has taken cagrisema. the study will also investigate the effect of warfarin before and after the participant takes cagrisema and assess if the injection site affects the level of cagrisema in the blood. the study will last for about 8 months.


Eligibility criteria:
inclusion criteria: * male or female. * aged 18-65 years (both inclusive) at the time of signing informed consent. * body mass index (bmi) between 27.0 and 39.9 kilograms per square meter (kg/m\^2) (both inclusive) at screening. overweight should be due to excess adipose tissue, as judged by the investigator. exclusion criteria: * previous dosing in a study with an amylin analogue. * presence or history of pathological bleeding tendencies, recent serious bleeding, recent myopathy or rhabdomyolysis, malignant hypertension and any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions including type 1 or type 2 diabetes mellitus. * presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator. * glycated haemoglobin (hba1c) greater than or equal to (≥) 6.5 % (48 millimoles per mole \[mmol/mol\]) at screening. * activated partial thromboplastin time (aptt) less than (\ ) 28.1 seconds (upper limit of normal \[unl) +0%) at screening. * prothrombin time \ 130% (unl-0%) at screening. * use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic cytochrome p450 (cyp) pathways, such as perikon (st. john's wort), ginseng, garlic, milk thistle, and echinaceae within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval), occasional use of paracetamol and highly effective contraceptives.
study of clotrimazole and hydroxyurea in patients with sickle cell syndromes

Conditions: Sickle Cell Anemia

Summary: objectives: determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes.

protocol outline: patients receive oral hydroxyurea either once or twice daily plus oral clotrimazole twice daily after meals for 6 months. patients are assessed at 3 and 6 months during treatment. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- sickle cell syndromes characterized by vaso-occlusive crises sufficiently severe to require prophylactic therapy three or more crises per year sufficiently severe to require hospitalization stable dose of hydroxyurea for at least 4 months required --prior/concurrent therapy-- no treatment with any other antisickling agents within the past 4 months biologic therapy: no transfusion within 90 days no concurrent chronic transfusions allowed (defined as more than one transfusion per month for 2 or more months) chemotherapy: see disease characteristics endocrine therapy: not specified radiotherapy: not specified surgery: not specified other: no chronic medications that alter neurologic, renal, or hepatic functions * patient characteristics-- performance status: karnofsky 70-100% hematopoietic: wbc within normal limits platelet count within normal limits hepatic: no history of chronic liver disease bilirubin less than 2 times normal sgot and sgpt less than 2.5 times normal no severe hepatic damage renal: creatinine within normal limits no severe renal damage neurologic: no severe neurologic impairment no recent or progressive neurologic impairment other: not pregnant fertile patients must use effective contraception no allergies to hydroxyurea or clotrimazole

Keywords: genetic diseases and dysmorphic syndromes hematologic disorders rare disease sickle cell anemia
sarcopenia and intervention physical therapy

Conditions: Sarcopenia

Summary: to evaluate and compare the effectiveness of neuromuscular electrical stimulation (nmes) and low-load resistance training with blood flow restriction (bfr) in improving muscle mass, strength, functional performance, and quality of life in elderly individuals diagnosed with sarcopenia

sarcopenia, the age-related decline in muscle mass, strength, and function, significantly affects the health and independence of elderly individuals. it increases the risk of frailty, falls, and disability. neuromuscular electrical stimulation (nmes) and low-load resistance training with blood flow restriction (bfr) are promising rehabilitation strategies for older adults with limited physical capacity. this study aims to compare the effectiveness of nmes and bfr in managing sarcopenia and improving physical and functional outcomes in the elderly

Eligibility criteria:
inclusion criteria: * older age (≥ 60-75 years) low muscle strength (e.g., low handgrip strength) low muscle mass (e.g., asm/height² below cutoff) exclusion criteria: * heart disese * kidny disese * autoimune disese * cognetive disorder * sever form of sarcopenia
effect of intraabdominal hypopressive exercises on postnatal backache and functional disability

Conditions: Low Back Pain

Summary: the purpose of this study was to evaluate the effectiveness of hypopressive exercise in postpartum females with abnormal hyperlordosis and back pain. hypopressive exercises are safe and beneficial for new moms, as they can be started soon after delivery. they help strengthen postural muscles, reduce back pain, and manage pain by reducing intra-abdominal pressure, increasing activity of postural musculature, and normalizing myofascial tension.

38 postpartum women with abnormal hyperlordosis. the women were then divided into two equal groups. group a(n=19) received hypopressive abdominal exercise along with traditional treatment for lower back pain (lbp), while group b(n=19) received the same treatment without hypopressive exercise. the main outcomes measured were the the revised short mcgill pain questionnaire version-2, the lumbar lordotic angle, and the patient-specific functional scale.

Eligibility criteria:
inclusion criteria: - participants must have a healthy pregnancy, a typical vaginal birth, lbp that existed 24 weeks after giving birth, and functional limitations in daily activities. the study only allowed women aged 20-35 with no more than two prior pregnancies and a bmi of less than 25 kg/m2 to participate. exclusion criteria: * women who under pharmacological or psychological treatment, had pelvic tumors, lumbar disk herniation, heart disease, hypertension, lumbar spine tumors, chronic uterine prolapse, chronic pelvic pain, lumbar spondylosis, or lumbar spondylolisthesis.

Keywords: postpartum low back pain quality of life